All four are in order, fastest above slowest — every timeframe pointing the same way.
Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.
The base has run 1.6 weeks and fell 10% from its ceiling at its deepest. The pivot is $17.02, and the stock closed 4.9% below it. Its relative strength rating is 87.
Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.
- Ex-dividendconfirmedin 11dEx-dividend dateNov 27, 2026
On average 11.3% either way across its last 8 reports.
Checking your subscription…
Close before the report day to close after it, so it holds whether the company reported before the open or after the close.
Twelve months to Sep 26, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.
What the numbers say
- Weak: Revenue -5.2% year over year, -3.3% on the quarter
- Good: Gross margin 32.4%, +1.7 points on the quarter
- Weak: Net loss $28M
- Good: Cash generating: operating cash flow $96M, free cash flow $79M
- Weak: Net debt $2.86B · cash $437M
From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.
None of the tracked funds held or sold it in their latest filings.
From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Nobody bought or sold on the open market in the last 6 months. There were 34 filings for awards, option exercises or shares withheld to pay tax — those happen on a vesting schedule, so they are not a decision to buy or sell.
From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.
Leaning is where price has been sitting against its own range while the range was quiet. It is not a forecast of which way the range opens up, and this site has no measurement that would support one.
7 of 7 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.
2 checks are not listed because this stock has too little history to judge them — a 200-day average needs 200 sessions. They are left out of the total rather than counted as failures.
These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.
Checking your subscription…
Checking your subscription…
No completed base to compare this one with yet.